zeposia
bristol-myers squibb pharma eeig - ozanimod hydrochloride - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunsuppressiva - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
zeposia 0.23 mg hartkapseln
bristol-myers squibb sa - ozanimodum - hartkapseln - ozanimodum 0.23 mg ut ozanimodi hydrochloridum 0.25 mg, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum conexum corresp. natrium max. 0.187 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172, drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172, pro capsula. - multiple sklerose, colitis ulcerosa - synthetika
zeposia 0.46 mg hartkapseln
bristol-myers squibb sa - ozanimodum - hartkapseln - ozanimodum 0.46 mg ut ozanimodi hydrochloridum 0.5 mg, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum conexum corresp. natrium max. 0.187 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172, drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172, pro capsula. - multiple sklerose, colitis ulcerosa - synthetika
zeposia 0.92 mg hartkapseln
bristol-myers squibb sa - ozanimodum - hartkapseln - ozanimodum 0.92 mg ut ozanimodi hydrochloridum 1, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum conexum corresp. natrium max. 0.187 mg, magnesii stearas, kapselhülle: gelatina, e 171, e 172, drucktinte: lacca, propylenglycolum, kalii hydroxidum, e 172, pro capsula. - multiple sklerose, colitis ulcerosa - synthetika
truscient
zoetis belgium sa - dibotermin alfa - knochenmorphogenetische proteine - hunde - osteoinduktives mittel zur behandlung von langbeinfrakturen als ergänzung zur chirurgischen standardbehandlung mit offener frakturreposition bei hunden.
xylanaest purum 2% - durchstechflaschen
gebro pharma gmbh - lidocain hydrochlorid monohydrat - lidocain
xylanaest purum 0,5% - durchstechflaschen
gebro pharma gmbh - lidocain hydrochlorid monohydrat - lidocain
xylanaest purum 1% - durchstechflaschen
gebro pharma gmbh - lidocain hydrochlorid monohydrat - lidocain
xylanaest purum 2% - ampullen
gebro pharma gmbh - lidocain hydrochlorid monohydrat - lidocain
mepinaest purum 1% - durchstechflaschen
gebro pharma gmbh - mepivacain hydrochlorid - mepivacain